By Fineline Cube 
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its global group revenues grew 7 % year‑on‑year (YoY) in constant currency terms over the first nine months of 2025. Topline sales reached CHF 45.86 billion (≈ USD 57.6 billion), driven by a 9 % rise in the Pharmaceuticals division to CHF 35.56 billion (≈ USD 44.66 billion). Diagnostics sales, however, posted only 1 % growth, reaching CHF 10.3 billion (≈ USD 12.9 billion).
Key Highlights
| Metric | Q1‑Q3 2025 | YoY % |
|---|---|---|
| Group Revenue | CHF 45.86 bn | +7 % |
| Pharma | CHF 35.56 bn | +9 % |
| Diagnostics | CHF 10.3 bn | +1 % |
| Full‑Year Guidance | Mid‑single‑digit sales growth | Unchanged |
| Core EPS | High single‑digit to low double‑digit | Up from prior high‑single‑digit range |
Diagnostics – China Drag Continues
Pricing controls in China have heavily weighed on the Diagnostics arm, pushing Asia‑Pacific sales down ‑15 % YoY. In contrast, other regions delivered robust growth:
- EMEA: +6 %
- North America: +7 %
- Latin America: +14 %
The 1 % global rise in Diagnostics sales is largely attributable to North American and Latin American gains offsetting the China slowdown.
Pharmaceuticals – Solid Global Expansion
Roche’s Pharma division benefited from a diversified portfolio and strong performance across all geographies:
| Region | Sales (CHF m) | YoY % |
|---|---|---|
| United States | 18,798 | +8 % |
| Europe | 6,818 | +5 % |
| Japan | 2,139 | +5 % |
| International | 7,800 | +13 % |
| Global | 35,555 | +9 % |
Key Growth Drivers
- Phesgo (breast‑cancer combination)
- Vabysmo (ophthalmology)
- Xolair (allergy & asthma)
- Hemlibra (hemophilia)
- Ocrevus (multiple sclerosis)
- Polivy (lymphoma ADC)
Pipeline Adjustments – 6 NMEs Terminated in Q3 2025
Roche’s investor presentation disclosed the removal of six new molecular entities (NMEs) from its pipeline:
| Phase | Molecule (assumed) | Target | Development Status |
|---|---|---|---|
| Phase I | SOF10 (anti‑TGF‑β1) | Solid tumors | Chugai |
| STA551 (CD137 switch antibody) | Solid tumors | Chugai | |
| Paralutide (RAS inhibitor) | Solid tumors | Chugai | |
| SAIL66 (anti‑CLDN6 trispecific) | CLDN6+ solid tumors | Chugai | |
| RG6436 (LepB inhibitor) | Urinary tract infection | Genentech | |
| Phase II | AMY109 (anti‑IL8 antibody) | Endometriosis | Chugai |
All five Chugai‑led projects were discontinued at the Phase I stage, while the Genentech‑led RG6436 was also terminated. The decision reflects a strategic refocus on high‑potential assets.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech